CN105168467A - 一种氟康唑复方胶囊及其制备方法 - Google Patents
一种氟康唑复方胶囊及其制备方法 Download PDFInfo
- Publication number
- CN105168467A CN105168467A CN201510583461.0A CN201510583461A CN105168467A CN 105168467 A CN105168467 A CN 105168467A CN 201510583461 A CN201510583461 A CN 201510583461A CN 105168467 A CN105168467 A CN 105168467A
- Authority
- CN
- China
- Prior art keywords
- parts
- fluconazol
- capsule
- fructus
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002775 capsule Substances 0.000 title description 43
- -1 Fluconazole compound Chemical class 0.000 title description 24
- 238000002360 preparation method Methods 0.000 title description 12
- 229960004884 fluconazole Drugs 0.000 title description 3
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 26
- 239000003814 drug Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 17
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 12
- 230000000844 anti-bacterial effect Effects 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000000843 powder Substances 0.000 description 7
- 239000000284 extract Substances 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000002386 leaching Methods 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 206010046914 Vaginal infection Diseases 0.000 description 3
- 201000008100 Vaginitis Diseases 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010007134 Candida infections Diseases 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 2
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 201000003984 candidiasis Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000003756 cervix mucus Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000007415 Anhedonia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000335423 Blastomyces Species 0.000 description 1
- 241000228405 Blastomyces dermatitidis Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241001668502 Cladophialophora carrionii Species 0.000 description 1
- 241000223203 Coccidioides Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- RTZKSTLPRTWFEV-OLZOCXBDSA-N Deoxygomisin A Chemical compound COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3C[C@@H](C)[C@@H](C)CC2=CC2=C1OCO2 RTZKSTLPRTWFEV-OLZOCXBDSA-N 0.000 description 1
- 241001480035 Epidermophyton Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- RTZKSTLPRTWFEV-UHFFFAOYSA-N Isokadsuranin Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3CC(C)C(C)CC2=CC2=C1OCO2 RTZKSTLPRTWFEV-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000555688 Malassezia furfur Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010034107 Pasteurella infections Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 208000008350 Pruritus Vulvae Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 206010042938 Systemic candida Diseases 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000008686 ergosterol biosynthesis Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 1
- 201000005115 pasteurellosis Diseases 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229930192961 schisandrol Natural products 0.000 description 1
- 229930193195 schizandrin Natural products 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种氟康唑复方胶囊;本发明还涉及一种氟康唑复方胶囊的制备方法,本发明的氟康唑复方阴道缓释片,该缓释片的组分及重量份数包括:氟康唑1~3份、黑枣17~25份、栀子13~23份、厚朴21~32份、垂盆草22~30份、五味子18~31份、茵陈17~29份、半枝莲20~30份、红枣19~33份、白芍15~27份,标本兼治阴道炎,快速缓解患者疼痛、瘙痒症状,使阴道分泌物恢复正常,提高了病人的依从性。
Description
技术领域
本发明属于局部用药领域,具体讲是一种氟康唑复方胶囊及其制备方法。
背景技术
阴道炎是妇女最常见的感染性疾病,其常见症状为阴道分泌物增多,外阴瘙痒、灼痛,可伴有尿频、尿痛及性交痛。妇科检查可见阴道分泌物增多,阴道粘膜充血或散在出血斑点,阴道后穹隆有多量白带,呈灰黄色或黄绿色脓性分泌物,有时呈泡沫状或白色稠厚凝乳或豆渣样。外阴可见水肿、抓痕、地图样红斑。
氟康唑具有广谱的抗菌作用,如念珠菌感染(包括免疫正常或免疫受损的人和动物的全身性念珠菌病)、新型隐球菌感染(包括颅内感染)、糠秕马拉色菌、小孢子菌属、毛癣菌属、表皮癣菌属、皮炎芽生菌、粗球孢子菌(包括颅内感染)及荚膜组织胞浆菌、斐氏着色菌、卡氏枝孢霉等有效。它的作用机制主要为高度选择性干扰真菌的细胞色素P-450的活性,从而抑制真菌细胞膜上麦角固醇的生物合成。但是氟康唑常引起消化道恶心、呕吐、腹痛或腹泻等副作用,并且可引起血清氨基转移酶升高,这就限制了氟康唑的广泛使用。
发明内容
为了提高氟康唑治疗阴道炎的疗效,减少氟康唑的副作用,本发明提供了一种氟康唑复方胶囊及其制备方法,该胶囊用于局部治疗阴道炎,直接作用于患处,起效快,疗效好,无毒副作用,可标本兼治阴道炎。
本发明目的是由以下技术方案实现的:
一种氟康唑复方胶囊,该胶囊的组分及重量份数包括:氟康唑1~3份、黑枣17~25份、栀子13~23份、厚朴21~32份、垂盆草22~30份、五味子18~31份、茵陈17~29份、半枝莲20~30份、红枣19~33份、白芍15~27份。
进一步的,一种氟康唑复方胶囊,该胶囊的组分及重量份数包括:氟康唑1~2份、黑枣21~23份、栀子16~19份、厚朴25~29份、垂盆草23~27份、五味子23~26份、茵陈21~26份、半枝莲24~26份、红枣22~26份、白芍18~23份。
进一步的,一种氟康唑复方胶囊,该胶囊的组分及重量份数包括:氟康唑2份、黑枣22份、栀子18份、厚朴27份、垂盆草25份、五味子25份、茵陈24份、半枝莲25份、红枣23份、白芍21份。
本发明还提供了一种氟康唑复方胶囊的制备方法,包括以下步骤:
1)备料,按照上述的组分及重量份数备料,氟康唑粉碎过100目筛;
2)中药原料药有效成分的提取:
①按照配比称取黑枣、栀子、厚朴、垂盆草、五味子、茵陈、半枝莲、红枣、白芍混合,混合后按照总重与蛤粉重量比为2:1加入蛤粉进行在120~160℃行进炒制,炒制完成后,去除蛤粉,然后放入粉碎机中粉碎并过100目筛,得粉碎粉;
②将质量浓度为50%的酒精加入中药提取罐中,酒精用量为中药原料重量份数的10倍,开启搅拌,将粉碎粉加入中药提取罐中,将中药提取罐内物料温度升温至77℃恒温提取30min,100目过滤取滤液,滤渣返回中药提取罐中重复提取一次,100目过滤取滤液,合并两次所得滤液,真空浓缩条件为:压力-0.07~-0.08Mpa、温度40~45℃,浓缩至相对密度为1.13~1.14的浓缩膏,浓缩膏于50℃干燥,过16目筛,得干燥粉;
3)装囊:将氟康唑粉与干燥粉混合,加入占胶囊总质量70~80%的糊精或淀粉,混匀,胶囊机制成胶囊,规格为氟康唑含量0.2~0.3g/粒。
为了提高氟康唑治疗阴道炎的疗效,提高病人的依从性,本发明通过大量筛选试验对中药原料药、药用辅料及制备工艺进行筛选,所选中药原料药:
黑枣性温味甘,富含蛋白质、糖类、有机酸、维生素B和维生素E,和磷、钙、铁等微量元素,还有各种营养元素,有补肾与养胃的功效,并对延缓衰老、增强机体活力、美容养颜都很有帮助。栀子提取物对肝细胞无毒性作用,栀子提取物可降低动物血清胆红素水平,并且栀子煎剂对白喉杆菌、金黄色葡萄球菌、伤寒杆菌有抑制作用,对多种皮肤真菌也有不同程度的抑制作用。厚朴味辛、性温,具有行气化湿、温中止痛、降逆平喘的功效,厚朴煎剂对葡萄球菌、链球菌、赤痢杆菌、巴氏杆菌、霍乱弧菌有较强的抗菌作用。五味子其果含有五味子素及维生素C、树脂、鞣质及少量糖类。有敛肺止咳、滋补涩精,五味子醇提取物能降低由四氯化碳、硫代乙醇胺等引起的实验动物谷丙转氨酶升高.γ-五味子素具抗肝损伤作用。茵陈有显著的保肝作用,对甲、乙型肝炎、黄疸型肝炎,有显著的疗效,并且茵陈增加胆汁中胆酸和胆红素排出的作用,能增加心脏冠脉血流量,改善微循环,并有降血压,降血脂。半支莲全草入药,具有清热解毒、活血祛瘀、消肿止痛、抗癌等功能,性寒味酸,全草含多种维生素、微量元素及氨基酸等成分,对金黄色葡萄球菌、福氏痢疾杆菌、伤寒杆菌、绿脓杆菌、大肠杆菌有抑制作用。红枣味甘、性温,能补中益气、养血生津,用于治疗脾虚弱、食少便溏、气血亏虚,对急慢性肝炎、肝硬化、贫血、过敏性紫癜等症有较好疗效。白芍含芍药甙、牡丹酚、芍药花甙,苯甲酸约1.07%、挥发油、脂肪油、树脂、鞣质、糖、淀粉、粘液质、蛋白质、β-谷甾醇和三萜类,对金黄色葡萄球菌有抑制作用,并具有保肝的作用。
所选药用辅料及工艺使胶囊能很好的释放药物有效成分,作用温和不刺激。
本发明的有益效果:
本发明的一种氟康唑复方胶囊为中西药合剂,有效克服了氟康唑只有单纯杀菌消炎并且引起反胃及肝脏损伤的缺陷,诸药协同作用效果好。栀子、垂盆草、五味子、茵陈、半枝莲、白芍相互协同作用能有效的起到保肝的作用,缓解氟康唑引起的转氨酶升高的副作用,厚朴、红枣相互作用能温中止痛、降逆平喘,缓解氟康唑引起的胃部不适。厚朴、半枝莲、五味子具有广谱的杀菌作用,可以辅助氟康唑进行杀菌,起到良好的治愈效果。
本发明的一种氟康唑复方胶囊,使用安全、无药物依赖性,毒副作用小,价格低廉。
具体实施方式
根据下述实施例,可以更好地理解本发明。然而,本领域的技术人员容易理解,实施例所描述的具体的物料配比、工艺条件及其结果仅用于说明本发明而不应当也不会限制权利要求书中所详细描述的本发明。
实施例1
一种氟康唑复方胶囊,该胶囊的组分及重量份数包括:氟康唑1份、黑枣17份、栀子13份、厚朴21份、垂盆草22份、五味子18份、茵陈17份、半枝莲20份、红枣19份、白芍15份。
一种氟康唑复方胶囊的制备方法,包括以下步骤:
1)备料,按照上述的组分及重量份数备料,氟康唑粉碎过100目筛;
2)中药原料药有效成分的提取:
①按照配比称取黑枣、栀子、厚朴、垂盆草、五味子、茵陈、半枝莲、红枣、白芍混合,混合后按照总重与蛤粉重量比为2:1加入蛤粉进行在120~160℃行进炒制,炒制完成后,去除蛤粉,然后放入粉碎机中粉碎并过100目筛,得粉碎粉;
②将质量浓度为50%的酒精加入中药提取罐中,酒精用量为中药原料重量份数的10倍,开启搅拌,将粉碎粉加入中药提取罐中,将中药提取罐内物料温度升温至77℃恒温提取30min,100目过滤取滤液,滤渣返回中药提取罐中重复提取一次,100目过滤取滤液,合并两次所得滤液,真空浓缩条件为:压力-0.07~-0.08Mpa、温度40~45℃,浓缩至相对密度为1.13~1.14的浓缩膏,浓缩膏于50℃干燥,过16目筛,得干燥粉;
3)装囊:将氟康唑粉与干燥粉混合,加入占胶囊总质量70~80%的糊精或淀粉,混匀,胶囊机制成胶囊,规格为氟康唑含量0.2~0.3g/粒。
用法用量:每晚1次,每次1~2粒,或遵医嘱。
实施例2
一种氟康唑复方胶囊,该胶囊的组分及重量份数包括:氟康唑3份、黑枣25份、栀子23份、厚朴32份、垂盆草30份、五味子31份、茵陈29份、半枝莲30份、红枣33份、白芍27份。
上述一种氟康唑复方胶囊的制备方法同实施例1。
实施例3
一种氟康唑复方胶囊,该胶囊的组分及重量份数包括:氟康唑1份、黑枣21份、栀子16份、厚朴25份、垂盆草23份、五味子23份、茵陈21份、半枝莲24份、红枣22份、白芍18份。
上述一种氟康唑复方胶囊的制备方法同实施例1。
实施例4
一种氟康唑复方胶囊,该胶囊的组分及重量份数包括:氟康唑2份、黑枣23份、栀子19份、厚朴29份、垂盆草27份、五味子26份、茵陈26份、半枝莲26份、红枣26份、白芍23份。
上述一种氟康唑复方胶囊的制备方法同实施例1。
实施例5
一种氟康唑复方胶囊,该胶囊的组分及重量份数包括:氟康唑2份、黑枣22份、栀子18份、厚朴27份、垂盆草25份、五味子25份、茵陈24份、半枝莲25份、红枣23份、白芍21份。
上述一种氟康唑复方胶囊的制备方法同实施例1。
实施例6抑菌试验检查
采用氟康唑阴道胶囊做对照,规格为20mg/片;实施例1所得一种氟康唑复方胶囊为实验组进行抑菌检查。
培养基的制备:称取牛肉浸膏5g溶于水800mL中,加入蛋白胨10g溶解,加入酪蛋白34g溶解,再加入NaCl5g溶解,调至pH7.6~7.8,稀释至1000mL。加入琼脂粉18g,高压灭菌15min,冷却至40℃~50℃时,倒板,凝固,放置无细菌污染的4℃冰箱备用。
菌种为:念珠菌
对照组抑菌液配制:将3片氟康唑阴道胶囊分别溶解在10ml无菌去离子水中,将药液浓度分别进行稀释,与原液比为1:2,1:4,1:8,1:16,1:32。
实验组抑菌液配制:将3片一种氟康唑复方胶囊分别溶解在10ml无菌去离子水中,将药液浓度分别进行稀释,与原液比为1:2,1:4,1:8,1:16,1:32。
抑菌结果如下:
结论:本发明的一种氟康唑复方胶囊有更好的杀菌效果。
以上实施方式只为说明本发明的技术构思及特点,其目的在于让熟悉此项技术的人了解本发明内容并加以实施,并不能以此限制本发明的保护范围,凡根据本发明精神实质所做的等效变化或修饰,都应涵盖在本发明的保护范围内。
Claims (4)
1.一种氟康唑复方胶囊,其特征在于,该胶囊的组分及重量份数包括:氟康唑1~3份、黑枣17~25份、栀子13~23份、厚朴21~32份、垂盆草22~30份、五味子18~31份、茵陈17~29份、半枝莲20~30份、红枣19~33份、白芍15~27份。
2.根据权利要求1所述的一种氟康唑复方胶囊,其特征在于,该胶囊的组分及重量份数包括:氟康唑1~2份、黑枣21~23份、栀子16~19份、厚朴25~29份、垂盆草23~27份、五味子23~26份、茵陈21~26份、半枝莲24~26份、红枣22~26份、白芍18~23份。
3.根据权利要求1所述的一种氟康唑复方胶囊,其特征在于,该胶囊的组分及重量份数包括:氟康唑2份、黑枣22份、栀子18份、厚朴27份、垂盆草25份、五味子25份、茵陈24份、半枝莲25份、红枣23份、白芍21份。
4.一种氟康唑复方胶囊的制备方法,其特征在于,包括以下步骤:
1)备料,按照权利要求1-3任一项所述的组分及重量份数备料,氟康唑粉碎过100目筛;
2)中药原料药有效成分的提取:
①按照配比称取黑枣、栀子、厚朴、垂盆草、五味子、茵陈、半枝莲、红枣、白芍混合,混合后按照总重与蛤粉重量比为2:1加入蛤粉进行在120~160℃行进炒制,炒制完成后,去除蛤粉,然后放入粉碎机中粉碎并过100目筛,得粉碎粉;
②将质量浓度为50%的酒精加入中药提取罐中,酒精用量为中药原料重量份数的10倍,开启搅拌,将粉碎粉加入中药提取罐中,将中药提取罐内物料温度升温至77℃恒温提取30min,100目过滤取滤液,滤渣返回中药提取罐中重复提取一次,100目过滤取滤液,合并两次所得滤液,真空浓缩条件为:压力-0.07~-0.08Mpa、温度40~45℃,浓缩至相对密度为1.13~1.14的浓缩膏,浓缩膏于50℃干燥,过16目筛,得干燥粉;
3)装囊:将氟康唑粉与干燥粉混合,加入占胶囊总质量70~80%的糊精或淀粉,混匀,胶囊机制成胶囊,规格为氟康唑含量0.2~0.3g/粒。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510583461.0A CN105168467A (zh) | 2015-09-15 | 2015-09-15 | 一种氟康唑复方胶囊及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510583461.0A CN105168467A (zh) | 2015-09-15 | 2015-09-15 | 一种氟康唑复方胶囊及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105168467A true CN105168467A (zh) | 2015-12-23 |
Family
ID=54891226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510583461.0A Pending CN105168467A (zh) | 2015-09-15 | 2015-09-15 | 一种氟康唑复方胶囊及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105168467A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1066785A (zh) * | 1992-04-21 | 1992-12-09 | 沈阳中药厂 | 茵山莲冲剂的制取方法 |
-
2015
- 2015-09-15 CN CN201510583461.0A patent/CN105168467A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1066785A (zh) * | 1992-04-21 | 1992-12-09 | 沈阳中药厂 | 茵山莲冲剂的制取方法 |
Non-Patent Citations (3)
Title |
---|
杨海涛等: "《呼吸系统疾病用药策略》", 30 November 2014 * |
王慧贤: "中西药合用治疗霉菌性阴道炎疗效观察", 《山西中医》 * |
胡仕琦等: "《肝病知识与咨询热点》", 31 March 2009 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105343625A (zh) | 一种排毒除湿利胆的蒲公英口服液及其制备方法 | |
CN101032593A (zh) | 一种治疗痤疮的中药制剂 | |
CN101732669A (zh) | 一种用于治疗妇科炎症的中药及其制备方法和应用 | |
CN105169017A (zh) | 一种治疗肾结石的中药及其制备方法 | |
KR20160119999A (ko) | 동의보감 원문에 근거한 국산 유기농 공진단 및 이의 제조방법 | |
CN101940621B (zh) | 一种润肠通便的中药组合物、制剂及其制备方法 | |
CN105168465A (zh) | 一种氟康唑复方阴道泡腾片及其制备方法 | |
CN101028490A (zh) | 一种治疗痤疮的中成药 | |
CN105168467A (zh) | 一种氟康唑复方胶囊及其制备方法 | |
CN103099885A (zh) | 具有祛痤疮功能软胶囊及其制备方法 | |
CN103127460B (zh) | 一种用于治疗妇科炎症的中药组合物及其制备方法 | |
CN105106840A (zh) | 祛痛消炎止呕汤 | |
CN105412596A (zh) | 一种治疗肝肿瘤的中药组合物及其制备方法 | |
CN104998158A (zh) | 一种治疗肝硬化的药物组合物及其应用 | |
CN105031439A (zh) | 一种用于治疗慢性牙周炎的药物制剂 | |
CN105031380A (zh) | 一种用于孕妇口腔局部麻醉的药物及其制备方法 | |
CN104352995A (zh) | 一种治疗胆结石的药物及其制备方法 | |
CN113952430B (zh) | 一种湿疹治疗用中草药复方制剂及其使用方法 | |
CN102872179B (zh) | 胃舒欣制剂的制备方法 | |
CN105853666A (zh) | 一种中药洗液及其制备方法 | |
CN105311542A (zh) | 一种盐酸特比萘芬复方组合物及制备方法和用途 | |
CN106511853A (zh) | 一种治疗皮肤病的外用药膏及其制备方法 | |
CN105106561A (zh) | 硝酸咪康唑复方阴道缓释泡腾片及制备方法 | |
CN104815131A (zh) | 一种用于治疗鸡痛风的药物组合物及其制备方法 | |
CN105661053A (zh) | 一种植物性羊饲料添加剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151223 |
|
RJ01 | Rejection of invention patent application after publication |